C
"Evaluating rates of cystoid macular
edema after dropless cataract surgery"
Paras Shah, MD, Mira Shiloach, MS, Marian Macsai, MD
Dr. Tipperman noted the continued theme of different
methods of drug delivery seen at the annual meeting,
leading him to select this paper.
Shah et al. conducted a retrospective analysis of cata-
ract surgeries from a single surgeon. Cases were grouped
by those who received conventional drops (group 1, topi-
cal steroids, NSAIDs, and antibiotics), those who received
a "dropless" regimen of subconjunctival injections of
triamcinolone acetate and intracameral and transzonular
moxifloxacin (group 2), and those who received intracam-
eral and transzonular moxifloxacin as in group 2 but were
given topical steroids (group 3). Those in group 2 had the
lowest rate of CME (1.8%), followed by group 1 (2.3%),
and group 3 (3%).
"This is something that I think has been bouncing
around in the journals … for a couple years now and there
hasn't been a consistent overall movement, but the ques-
tion is what are people doing for their drop regimen and
where will we be going as some of the newer agents come
out for us," Dr. Tipperman said.
Editors' note: The session is available on demand for those who
attended the 2019 ASCRS ASOA Annual Meeting.
Dr. Tipperman presents his selections for the Best of ASCRS 2019
Cataract papers.
Source: ASCRS
